The hippocampus, a seahorse-shaped structure deep in the temporal lobe, is famously sensitive to interruptions in its blood supply. Within this structure, a narrow band of neurons called the CA1 region is particularly fragile. In humans, cardiac arrest and other events that briefly starve the brain of oxygen can wipe out CA1 neurons days after circulation has been restored, a phenomenon known as delayed neuronal death. Researchers have long used the gerbil as a model for this process, because transient occlusion of the two carotid arteries in these animals produces a remarkably reproducible pattern of CA1 injury that mirrors what is seen in human patients. It is precisely this model that the Korean team deployed to probe the role of SIRT3, a mitochondrial deacetylase enzyme that sits at the intersection of cellular metabolism and oxidative stress.

SIRT3 belongs to the sirtuin family of enzymes, a group of protein-modifying molecules that have attracted intense interest for their roles in aging, metabolism, and stress resistance. Unlike its cousins SIRT1 and SIRT2, which operate largely in the nucleus and cytoplasm, SIRT3 works almost exclusively inside mitochondria. There, it removes chemical acetyl groups from metabolic enzymes, fine-tuning the machinery that converts nutrients into usable energy and keeping the organelle’s antioxidant defenses primed. When SIRT3 activity falters, mitochondria tend to leak more reactive oxygen species, the chemically aggressive byproducts of respiration that can damage DNA, proteins, and membranes. Because neurons are extraordinarily dependent on mitochondrial function and comparatively poor at buffering oxidative damage, SIRT3 has emerged as a compelling candidate for explaining why some neurons die after ischemia while others survive.

To test this idea, the researchers first mapped how SIRT3 behaves in the hippocampus after a temporary ischemic insult. In sham-operated animals that underwent surgery without artery occlusion, SIRT3 immunoreactivity, a staining technique that reveals where the protein is abundant, was found predominantly in hippocampal neurons. But two days after ischemia and reperfusion, the signal dropped significantly, indicating that the ischemic episode had depleted the CA1 region of this mitochondrial guardian. This temporal pattern set the stage for the central experiment: could restoring SIRT3 levels pharmacologically change the outcome?

Enter adjudin. The compound, which has been investigated in earlier research for its effects on SIRT3 expression, was administered to gerbils undergoing the ischemia procedure. The results were striking on several fronts. Adjudin treatment pushed SIRT3 immunoreactivity in the CA1 region above the levels seen in vehicle-treated animals after ischemia and reperfusion, effectively reversing the ischemia-induced decline. More importantly, the biochemical change was accompanied by tangible protection of brain tissue and function. Animals receiving adjudin showed significantly less delayed neuronal death in the CA1 region, the very population of cells that normally succumbs in the days following the insult.

The behavioral consequences of this protection were equally notable. Ischemia in this model typically produces locomotor hyperactivity, a measurable increase in movement that reflects the functional loss of the hippocampal circuitry. Adjudin administration significantly attenuated this hyperactivity, suggesting that the preserved neurons were still doing their job. For a field where many candidate neuroprotective agents have failed to translate from tissue-level effects into functional benefits, this pairing of histological rescue with behavioral improvement is a meaningful combination, even at the preclinical stage.

Digging into the mechanisms, the team found that adjudin markedly suppressed the surge of reactive oxygen species that follows ischemia and reperfusion. At the same time, the treatment increased immunoreactivity for glutathione peroxidase, an antioxidant enzyme that neutralizes peroxides, to levels above even those observed in sham-operated animals. This dual effect, dampening the production of damaging oxidants while boosting the cellular machinery that disposes of them, is consistent with SIRT3’s known role as a regulator of mitochondrial antioxidant capacity. The data paint a coherent picture in which the ischemia-driven loss of SIRT3 leaves mitochondria defenseless, allowing oxidative stress to accumulate until neurons cross the threshold into delayed death.

The protective effects extended beyond oxidative stress into the realm of neuroinflammation. Following ischemia, microglia, the resident immune cells of the brain, activate and migrate toward damaged tissue, releasing pro-inflammatory cytokines such as interleukin-1 beta and interleukin-6. While this response is intended to clear debris and coordinate repair, excessive or prolonged activation can itself injure surrounding neurons. In the adjudin-treated animals, the researchers observed inhibited microglial activation and decreased production of both interleukin-1 beta and interleukin-6 in the hippocampus. By quieting this inflammatory storm, adjudin appears to interrupt a second wave of damage that compounds the initial oxidative insult, offering a two-pronged defense for the embattled CA1 neurons.

The authors are careful to note an important limitation of their work. Because SIRT3 deacetylase activity and SIRT3 dependence were not directly assessed in the study, the data do not establish a SIRT3-dependent mechanism. In other words, while adjudin increased SIRT3 immunoreactivity and simultaneously reduced oxidative stress, inflammation, and neuronal death, the experiments did not prove that SIRT3 is the causal link between the two. Adjudin could conceivably act through additional pathways, and the observed correlation between SIRT3 levels and neuroprotection, however suggestive, remains just that. This kind of methodological honesty is increasingly valued in preclinical neuroscience, a field that has grappled with reproducibility concerns and with the temptation to overstate mechanistic claims.

Even with that caveat, the study offers a clear roadmap for future research. If follow-up experiments using SIRT3 knockdown or pharmacological inhibition confirm that the enzyme is genuinely required for adjudin’s protective effects, the case for SIRT3 as a therapeutic target in ischemic brain injury would become substantially stronger. The broader implications are considerable: cerebral ischemia underlies not only stroke and cardiac arrest but also contributes to cognitive decline in conditions ranging from vascular dementia to Alzheimer’s disease, and mitochondrial dysfunction is a common thread running through many of them. For now, the image that emerges from this gerbil study is an intriguing one, a drug that replenishes a mitochondrial guardian just as the brain’s most fragile neurons need it most, buying them time to survive an insult that would otherwise prove fatal. Whether that image will hold up in more rigorous mechanistic tests, and ultimately in the clinic, is the question the next round of experiments must answer.

Subject of Research: Neuroprotective effects of adjudin on ischemic hippocampal injury and SIRT3 expression in a gerbil model of transient forebrain ischemia

Article Title: Adjudin attenuates ischemic hippocampal damage in gerbils in association with increased SIRT3 immunoreactivity

Article References: Hahn, K. R., Kwon, H. J., Go, H., Moon, S. M., Jung, H. Y., Kim, D. W., Kim, W., & Yoo, D. Y. (2026). Adjudin attenuates ischemic hippocampal damage in gerbils in association with increased SIRT3 immunoreactivity. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01056-9

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01056-9

Keywords: SIRT3, adjudin, cerebral ischemia, hippocampus, CA1 neurons, delayed neuronal death, reactive oxygen species, glutathione peroxidase, microglial activation, neuroinflammation, mitochondrial dysfunction, gerbil model

The research team, led by Ju Xi with colleagues Zhao Feng and Yu Heming, used the gold-standard rodent model of ischemic stroke: transient middle cerebral artery occlusion followed by reperfusion, abbreviated MCAO/R. In this model, a filament is threaded into the cerebral artery to block it, then withdrawn after a defined interval so that blood surges back into the oxygen-starved tissue — reproducing in miniature what happens in human patients after clot removal. Rats were divided into five groups: healthy controls, animals subjected to ischemia/reperfusion alone, animals treated with the clinical calcium-channel blocker nimodipine at 1.4 milligrams per kilogram of body weight as a positive control, animals given monotropein at 40 milligrams per kilogram, and animals receiving monotropein alone without any ischemic insult. Across a battery of behavioral, biochemical, histological, and molecular assays, the treated animals told a strikingly consistent story.

The most immediately visible outcome concerned neurological function and brain swelling. Rats that had suffered reperfusion injury but received monotropein scored significantly better on standardized neurological deficit tests than their untreated counterparts, with p-values below 0.05. Brain water content — a direct proxy for the cerebral edema that makes stroke so dangerous by raising intracranial pressure — was markedly reduced. The compound also blunted lipid peroxidation, measured through levels of malondialdehyde (MDA), a degradation product that serves as a fingerprint of free-radical attack on cell membranes. Perhaps most notably, monotropein outperformed nimodipine, a drug already used in clinical practice for its cerebrovascular effects, on these antioxidant and edema metrics, while boosting the brain’s endogenous antioxidant defenses including superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and reduced glutathione (GSH).

Under the microscope, the protective effects became even more concrete. Quantitative histopathology of the hippocampus — a brain region exquisitely vulnerable to ischemic damage and central to memory — showed that monotropein-treated animals retained far more intact neuronal architecture. The ischemia/reperfusion injury alone produced the expected devastation: disorganized tissue layers, degenerating neurons, and karyopyknosis, the shrunken, darkly staining nuclei that signal cells undergoing irreversible condensation of chromatin on their way to death. In the monotropein group, these hallmarks of neurodegeneration were visibly attenuated. The researchers complemented the structural assessment with molecular profiling of the apoptotic machinery, finding that the compound upregulated the anti-death protein Bcl-2 while repressing mRNA levels of the pro-apoptotic factors Bax, Bad, and Caspase-3 — a shift in the Bcl-2 family balance that favors cellular survival over self-destruction.

But the paper’s central claim goes beyond classical apoptosis. The authors argue that monotropein’s most important action is on pyroptosis, an inflammatory form of programmed cell death executed by gasdermin pores that rupture the cell membrane and spill their contents into surrounding tissue. Pyroptosis is driven by the NLRP3 inflammasome, a multi-protein complex that assembles when the cell senses danger signals. Once NLRP3 oligomerizes with its adaptor protein ASC and recruits pro-caspase-1, the activated enzyme cleaves and activates interleukin-1β and other pyrogens, turning a single injured cell into a beacon that recruits and inflames its neighbors. In stroke, this amplification loop is widely considered a major driver of the expanding lesion, which is why pharmacological suppression of NLRP3 has become one of the most intensively pursued strategies in neuroprotection research.

Consistent with this mechanism, the molecular analysis revealed that monotropein treatment sharply decreased the immunohistochemical expression of the pro-inflammatory cytokines IL-6 and TNF-α, along with the master transcription factor NF-κB, which coordinates the transcriptional response to inflammatory stimuli. More specifically, the study demonstrated downregulation across the MAPK/p65/NLRP3/ASC signaling axis — suppressing the mitogen-activated protein kinase JNK, the p38 MAPK isoform, the NF-κB p65 subunit, and the NLRP3 and ASC inflammasome components themselves. In effect, the compound appears to act at multiple layers of the inflammatory hierarchy simultaneously: damping the upstream kinase cascades that activate inflammation, restraining the transcription factors that write inflammatory genes, and disassembling the inflammasome complex that manufactures the most potent inflammatory signals.

What distinguishes this study from much of the natural-product pharmacology literature is its integrated computational component. The researchers performed in silico molecular docking to model how monotropein physically interacts with the key proteins of the pathway. The predicted binding affinities were strongest for JNK, with a docking score of −8.5 kcal/mol, followed by the CARD domain at −7.4 kcal/mol, NLRP3 at −7.1 kcal/mol, p38 MAPK at −5.8 kcal/mol, and NF-κB at −4.2 kcal/mol. When the team refined the most promising poses using Induced Fit Docking — a protocol that allows both the ligand and the binding pocket to flex and adapt to one another — the scores improved further to −9.4 kcal/mol for JNK and −8.7 kcal/mol for CARD. For context, docking scores below roughly −7 kcal/mol are generally considered indicative of meaningful binding, placing monotropein’s predicted interactions with JNK and the CARD domain in the range typically associated with potent small-molecule inhibitors.

Docking, however, is only a static snapshot, so the team followed up with molecular dynamics simulations, which track the motion of the protein–ligand complexes over time in a realistic simulated solvent. The trajectory analyses using root-mean-square deviation and root-mean-square fluctuation measures — standard metrics for assessing whether a ligand stays bound and whether the protein remains structurally stable — confirmed that the monotropein complexes held together throughout the simulation. Persistent hydrogen-bonding contacts and hydrophobic interactions between the ligand and its targets were maintained across the simulated time course, lending computational support to the idea that the compound’s binding is not a fleeting artifact of the docking algorithm but a stable physical association. This combination of in vivo efficacy and in silico mechanistic plausibility forms the integrated analysis announced in the paper’s subtitle.

The findings also fit coherently into monotropein’s growing pharmacological dossier. Previous work has shown the compound suppressing NF-κB-driven inflammation in macrophages and colitis models, protecting osteoblasts and chondrocytes from oxidative stress, apoptosis, and pyroptosis, mitigating sepsis-induced acute lung injury, easing cisplatin nephrotoxicity, and even alleviating sepsis-associated encephalopathy by targeting matrix metalloproteinase-9. The NLRP3 inflammasome has likewise been repeatedly implicated in ischemia/reperfusion injury across multiple organs, and several other natural products and repurposed drugs have been reported to act through this pathway. What the Nanjing study adds is a direct demonstration in a rigorous stroke model, with a clinically relevant comparator drug, a defined molecular axis, and computational evidence that helps explain the selectivity of the effect across the pathway’s components.

Important caveats remain before any celebration is warranted. The work was conducted entirely in rats, at a single dose of 40 milligrams per kilogram, and rodent stroke models have a long and sobering history of translation failures; interventions that look spectacular in MCAO/R animals frequently falter in human trials. The pharmacokinetics, blood–brain barrier penetration, safety profile, and optimal dosing of monotropein in humans remain uncharacterized, and the computational predictions, however elegant, will need to be validated with direct biochemical assays — for example, demonstrating reduced caspase-1 activation or gasdermin-D cleavage in treated tissue. Still, the convergence of behavioral rescue, histological protection, antioxidant restoration, anti-apoptotic signaling, and inflammasome suppression in a single natural product is exactly the kind of multi-layered profile that neuroprotective drug development has struggled to achieve. If future studies confirm the mechanism and translate the dosing, monotropein — or derivatives inspired by it — could join the short list of candidates aimed at the inflammatory aftermath of stroke, where current medicine has little to offer beyond speedy reperfusion.

Subject of Research: Neuroprotective effects of monotropein on NLRP3-mediated pyroptosis in cerebral ischemia/reperfusion injury

Article Title: Monotropein alleviates neuroinflammation in a rat model of cerebral ischemia/reperfusion injury by regulating NLRP3-mediated pyroptosis: an integrated in vivo and in silico analysis

Article References: Xi, J., Feng, Z., & Heming, Y. (2026). Monotropein alleviates neuroinflammation in a rat model of cerebral ischemia/reperfusion injury by regulating NLRP3-mediated pyroptosis: an integrated in vivo and in silico analysis. 3 Biotech, 16(10), Article 436. https://doi.org/10.1007/s13205-026-05069-3

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05069-3

Keywords: monotropein, stroke, cerebral ischemia, reperfusion injury, NLRP3 inflammasome, pyroptosis, neuroinflammation, Morinda officinalis, molecular docking, apoptosis, oxidative stress, neuroprotection